Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
== Available forms == A branded version of the drug is owned by Astellas Pharma, and is sold under the brand name Prograf, given twice daily. A number of other manufacturers hold marketing authorisation for alternative brands of the twice-daily formulation. Once-daily formulations with marketing authorisation include Advagraf (Astellas Pharma) and Envarsus (marketed as Envarsus XR in US by Veloxis Pharmaceuticals and marketed in Europe by Chiesi). These formulations are intended to reduce pharmacokinetic variation in blood levels and facilitate compliance with dosing. The topical formulation is marketed by LEO Pharma under the name Protopic.
=== 1976 === January 8: Chinese Premier Zhou Enlai dies of cancer. February: Soviet and Cuban forces install a communist government in Angola. March 24: The National Reorganization Process takes power in Argentina following a successful military coup and launches military action against Argentine-based guerrillas. Jorge Rafael Videla is installed as president. May 4: The Corsican conflict begins, with the aim of an independent Corsican state against the French government by Corsican nationalists. June 29: The Seychelles becomes independent from the UK, as a republic in the Commonwealth of Nations. July 2: Vietnam is officially reunited under a communist regime. July 20: U.S. Military personnel withdraw from Thailand. September 1: Inception of Safari Club. September 9: Death of Mao Zedong. December 4: Insurgency in Aceh begins. Jean-Bédel Bokassa proclaimed himself as Emperor of the Central African Empire.
In the past, fishing vessels were restricted in range by the simple consideration that the catch must be returned to port before it spoils and becomes worthless. The development of refrigeration and freezing technologies transformed the commercial fishing industry: fishing vessels could be larger, spending more time away from port and therefore accessing fish stocks at a much greater distance. Refrigeration and freezing also allow the catch to be distributed to markets further inland, reaching customers who previously would have had access only to dried or salted sea fish. Canning, developed during the 19th century, has also had a significant impact on fishing by allowing seasonal catches of fish that are possibly far from large centres of population to be exploited. For example: canned sardines. Preservation techniques are needed to prevent fish spoilage and lengthen shelf life. They are designed to inhibit the activity of spoilage bacteria and the metabolic changes that result in the loss of fish quality. Spoilage bacteria are the specific bacteria that produce the unpleasant odours and flavours associated with spoiled fish. Fish normally host many bacteria that are not spoilage bacteria, and most of the bacteria present on spoiled fish played no role in the spoilage. To flourish, bacteria need the right temperature, sufficient water and oxygen, and surroundings that are not too acidic. Preservation techniques work by interrupting one or more of these needs. Preservation techniques can be classified as follows.
== Prognosis == The prognosis depends on the underlying cause. Obesity- and insulin resistance–related forms often improve with weight loss and metabolic control. Drug-induced cases typically resolve with withdrawal of the causative agent. Hereditary variants may persist. Malignancy-associated acanthosis nigricans may regress following tumour treatment.
== Mechanism of action == BDNF binds at least two receptors on the surface of cells that are capable of responding to this growth factor, TrkB (pronounced "Track B") and the LNGFR (for low-affinity nerve growth factor receptor, also known as p75). It may also modulate the activity of various neurotransmitter receptors, including the Alpha-7 nicotinic receptor. BDNF has also been shown to interact with the reelin signaling chain. The expression of reelin by Cajal–Retzius cells goes down during development under the influence of BDNF. The latter also decreases reelin expression in neuronal culture.
Sources: en.wikipedia.org
The United States military began executing airstrikes on vessels in the Caribbean Sea in September 2025, described by the administration of President Donald Trump as part of an effort to fight the flow of illicit drugs from Latin America to the US. In October, the strikes expanded to include vessels in the Eastern Pacific Ocean. The Trump administration has alleged, without producing public evidence, that the vessels were operated by groups it designated as narcoterrorists, including the Venezuelan organization Tren de Aragua and the Colombian far-left guerilla group National Liberation Army. As part of what was later unveiled as Operation Southern Spear, the US began deploying Navy warships and personnel to the Caribbean in mid-August. Trump announced on 2 September that the US Navy had carried out the first airstrike in the Caribbean on a boat from Venezuela, killing all 11 people aboard; he released a video of the incident, which Venezuelan sources said had occurred on 1 September. US officials said that this was a military operation against drug cartels in Latin America and that these military operations would continue. As of 19 September 2026, at least 234 people had been killed (including 17 who are missing and presumed dead) in at least 78 strikes on over 79 vessels and the US had made its first strike on a land target within Venezuela. On 12 June, Niño Guerrero, leader of Tren de Aragua, was killed in joint operation with the post-Maduro Venezuelan government.
The likelihood of ionization is a function of the filament temperature, the work function of the filament substrate and the ionization energy of the element. This is summarised in the Saha–Langmuir equation:
The Helsinki Accords, in which the Soviets promised to grant free elections in Europe, has been called a major concession to ensure peace by the Soviets. In practice, the Soviet government significantly curbed the rule of law, civil liberties, protection of law, and guarantees of property, which were considered examples of "bourgeois morality" by Soviet legal theorists such as Andrey Vyshinsky. The Soviet Union signed legally-binding human rights documents, such as the International Covenant on Civil and Political Rights in 1973 and the Helsinki Accords in 1975, but they were neither widely known or accessible to people living under communist rule, nor were they taken seriously by the communist authorities. Human rights activists in the Soviet Union were regularly subjected to harassment, repressions and arrests. The pro-Soviet American business magnate Armand Hammer of Occidental Petroleum often mediated trade relations. Author Daniel Yergin, in his book The Prize, writes that Hammer "ended up as a go-between for five Soviet General Secretaries and seven US Presidents." Hammer had extensive business relationship in the Soviet Union stretching back to the 1920s with Lenin's approval.
=== Fetus earrings === During the 1984 exhibition of freeze-dried sculptures in London, Gibson was given two dehydrated human fetuses from an anatomy professor. They were 10 weeks in development and had been dehydrated for 20 years. Gibson re-hydrated both fetuses, freeze-dried them and attached them as earrings to a female mannequin head. The sculpture was titled Human Earrings. They were exhibited at the Young Unknowns Gallery in south London in December 1987. On Thursday, 3 December 1987, the sculpture was seized by the Metropolitan Police. Because of this incident, Gibson was expelled from Goldsmiths College on 21 December 1987, where he was studying post-graduate art, design and technology. On 11 April 1988, Gibson and the gallery owner, Peter Sylveire, were formally charged with the common law offences of exhibiting a public nuisance and outraging public decency. The trial started on Monday, 30 January 1989 at the Old Bailey in central London. The judge was Brian Smedley, Michael Worsley was the prosecuting barrister, and Geoffrey Robertson and Helena Kennedy were the defence barristers. On 6 February 1989, the charge of public nuisance was dismissed. On Tuesday, 9 February 1989, the jury of 10 women and 2 men found Gibson and Sylveire guilty of outraging public decency. Gibson was fined £500 and Sylveire was fined £300. Immediately following the verdict, an appeal application was filed. However, on 10 July 1990, the Court of Appeal dismissed the case and upheld the earlier conviction.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.